Fri, Nov 20, 2026中文About
Filings today 284 / Covered 15
Source: TDnet timely disclosures
Updated 11/20 20:30M&A / TOB 20 Guidance 7 Buybacks 11 Dividends 4 Capital 12 Earnings 16 People 3

Kaken Seiyaku H1 net profit jumps 698.1% to ¥8.0 billion on J&J milestone

Mon, Nov 09, 2026 15:30 JST Kaken Seiyaku (4521.T) Pharmaceutical 中文

Kaken Seiyaku (4521) said first-half net profit attributable to owners of the parent rose 698.1% to ¥8.0 billion, driven by a US$70 million milestone payment from Johnson & Johnson.

H1 net profit¥8.0 billion (+698.1%)
H1 sales¥48.96 billion (+24.4%)
J&J milestone incomeUS$70 million
Merger effective dateDec. 31, 2026

For the six months ended Sept. 30, 2026, the company attributed higher sales and profit to increased overseas sales after it received the milestone income under a license agreement with J&J announced on April 22, 2026. Earnings per share were ¥211.29. R&D expenses fell 14.8% to ¥9.94 billion.

ItemH1 FY3/2027H1 FY3/2026
Sales¥48.96 billion¥39.36 billion
Operating profit¥10.16 billion¥180 million
Ordinary profit¥10.71 billion¥584 million
Net profit¥8.00 billion¥1.00 billion

Kaken Seiyaku kept its full-year forecast unchanged: sales of ¥89.9 billion, up 17.0%, operating profit of ¥7.9 billion and net profit of ¥6.5 billion, up 203.1%. It declared an interim dividend of ¥95 per share and maintained its annual dividend forecast of ¥190.

During the period, the company filed for marketing approval for KP-001, for refractory vascular malformations, and KAR, for head lice. Its European licensee Almirall launched nail fungus treatment Jublia in Germany, the group's first product in the European market.

The board also approved the absorption of wholly owned subsidiary ARTham Therapeutics, a drug research company with capital of ¥100 million. As a simplified and short-form merger, it requires no shareholder approval and involves no allotment of shares or cash. The company said the impact on consolidated results will be minor.

Next steps: Kaken Seiyaku plans to file its semiannual report on Nov. 12, 2026, and begin dividend payments on Nov. 30, 2026. The merger is scheduled to take effect on Dec. 31, 2026.


Original filings
Related